Literature DB >> 3510571

Continuation drug therapy for major depressive episodes: how long should it be maintained?

R F Prien, D J Kupfer.   

Abstract

A major problem for the practitioner is the lack of satisfactory guidelines as to how long continuation drug treatment of depressive episodes must be maintained to ensure that the episode is over. This often leads to either premature withdrawal of the drug and subsequent relapse or unnecessarily prolonged treatment. Results from a collaborative project of the National Institute of Mental Health provide the first study-derived guidelines on the length of continuation therapy. Findings indicate that withdrawal of such therapy is safe only after the patient has been free of significant symptoms for 16 to 20 weeks and that focusing on mild as well as severe symptoms is critical in this decision.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3510571     DOI: 10.1176/ajp.143.1.18

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  30 in total

1.  Assessment of subclinical symptoms and psychological well-being in depression.

Authors:  G A Fava; L Mangelli
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2001       Impact factor: 5.270

2.  Measurement-based care for unipolar depression.

Authors:  David W Morris; Madhukar H Trivedi
Journal:  Curr Psychiatry Rep       Date:  2011-12       Impact factor: 5.285

Review 3.  Continuation and maintenance therapy with antidepressive agents. An overview of research.

Authors:  A J Loonen; G J Zwanikken
Journal:  Pharm Weekbl Sci       Date:  1990-08-24

Review 4.  Managing depression in primary care.

Authors:  N Freemantle; F Song; T A Sheldon; P Watson; J M Mason; A F Long
Journal:  Qual Health Care       Date:  1993-03

Review 5.  Continuation and maintenance therapy of early-onset major depressive disorder.

Authors:  Graham J Emslie; Taryn L Mayes; Maryse Ruberu
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

Review 6.  Pharmacologic treatment of depression in late life.

Authors:  A J Flint
Journal:  CMAJ       Date:  1997-10-15       Impact factor: 8.262

Review 7.  The pharmacotherapy of depression.

Authors:  R T Joffe
Journal:  J Psychiatry Neurosci       Date:  1991-07       Impact factor: 6.186

Review 8.  Partial remission, residual symptoms, and relapse in depression.

Authors:  E S Paykel
Journal:  Dialogues Clin Neurosci       Date:  2008       Impact factor: 5.986

Review 9.  Pharmacotherapy to sustain the fully remitted state.

Authors:  Sidney Kennedy; Roger McIntyre; Angelo Fallu; Raymond Lam
Journal:  J Psychiatry Neurosci       Date:  2002-07       Impact factor: 6.186

10.  Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after successful acute treatment of mild to moderate depression--rationale and study design.

Authors:  S Kasper; A Dienel; M Kieser
Journal:  Int J Methods Psychiatr Res       Date:  2004       Impact factor: 4.035

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.